894 related articles for article (PubMed ID: 26797965)
1. Bronchoscopy-guided antimicrobial therapy for cystic fibrosis.
Jain K; Wainwright C; Smyth AR
Cochrane Database Syst Rev; 2016 Jan; (1):CD009530. PubMed ID: 26797965
[TBL] [Abstract][Full Text] [Related]
2. Bronchoscopy-guided antimicrobial therapy for cystic fibrosis.
Jain K; Wainwright C; Smyth AR
Cochrane Database Syst Rev; 2013 Dec; (12):CD009530. PubMed ID: 24363033
[TBL] [Abstract][Full Text] [Related]
3. Bronchoscopy-guided antimicrobial therapy for cystic fibrosis.
Jain K; Wainwright C; Smyth AR
Cochrane Database Syst Rev; 2018 Sep; 9(9):CD009530. PubMed ID: 30221745
[TBL] [Abstract][Full Text] [Related]
4. Bronchoscopy-guided antimicrobial therapy for cystic fibrosis.
Jain K; Wainwright CE; Smyth AR
Cochrane Database Syst Rev; 2024 May; 5(5):CD009530. PubMed ID: 38700027
[TBL] [Abstract][Full Text] [Related]
5. Standard versus biofilm antimicrobial susceptibility testing to guide antibiotic therapy in cystic fibrosis.
Waters V; Ratjen F
Cochrane Database Syst Rev; 2017 Oct; 10(10):CD009528. PubMed ID: 28981972
[TBL] [Abstract][Full Text] [Related]
6. Effect of bronchoalveolar lavage-directed therapy on Pseudomonas aeruginosa infection and structural lung injury in children with cystic fibrosis: a randomized trial.
Wainwright CE; Vidmar S; Armstrong DS; Byrnes CA; Carlin JB; Cheney J; Cooper PJ; Grimwood K; Moodie M; Robertson CF; Tiddens HA;
JAMA; 2011 Jul; 306(2):163-71. PubMed ID: 21750293
[TBL] [Abstract][Full Text] [Related]
7. Standard versus biofilm antimicrobial susceptibility testing to guide antibiotic therapy in cystic fibrosis.
Waters V; Ratjen F
Cochrane Database Syst Rev; 2015 Mar; (3):CD009528. PubMed ID: 25741986
[TBL] [Abstract][Full Text] [Related]
8. Standard versus biofilm antimicrobial susceptibility testing to guide antibiotic therapy in cystic fibrosis.
Smith S; Waters V; Jahnke N; Ratjen F
Cochrane Database Syst Rev; 2020 Jun; 6(6):CD009528. PubMed ID: 32520436
[TBL] [Abstract][Full Text] [Related]
9. Antibiotic strategies for eradicating Pseudomonas aeruginosa in people with cystic fibrosis.
Langton Hewer SC; Smyth AR
Cochrane Database Syst Rev; 2017 Apr; 4(4):CD004197. PubMed ID: 28440853
[TBL] [Abstract][Full Text] [Related]
10. Treatments for preventing recurrence of infection with Pseudomonas aeruginosa in people with cystic fibrosis.
Palser S; Smith S; Nash EF; Agarwal A; Smyth AR
Cochrane Database Syst Rev; 2019 Dec; 12(12):CD012300. PubMed ID: 31845758
[TBL] [Abstract][Full Text] [Related]
11. Combination antimicrobial susceptibility testing for acute exacerbations in chronic infection of Pseudomonas aeruginosa in cystic fibrosis.
Waters V; Ratjen F
Cochrane Database Syst Rev; 2017 Jun; 6(6):CD006961. PubMed ID: 28628280
[TBL] [Abstract][Full Text] [Related]
12. Standard versus biofilm antimicrobial susceptibility testing to guide antibiotic therapy in cystic fibrosis.
Waters V; Ratjen F
Cochrane Database Syst Rev; 2012 Nov; 11():CD009528. PubMed ID: 23152277
[TBL] [Abstract][Full Text] [Related]
13. Combination antimicrobial susceptibility testing for acute exacerbations in chronic infection of Pseudomonas aeruginosa in cystic fibrosis.
Smith S; Ratjen F; Remmington T; Waters V
Cochrane Database Syst Rev; 2020 May; 5(5):CD006961. PubMed ID: 32412092
[TBL] [Abstract][Full Text] [Related]
14. Antibiotic strategies for eradicating Pseudomonas aeruginosa in people with cystic fibrosis.
Langton Hewer SC; Smyth AR
Cochrane Database Syst Rev; 2014 Nov; (11):CD004197. PubMed ID: 25383937
[TBL] [Abstract][Full Text] [Related]
15. Prophylactic anti-staphylococcal antibiotics for cystic fibrosis.
Smyth AR; Rosenfeld M
Cochrane Database Syst Rev; 2017 Apr; 4(4):CD001912. PubMed ID: 28417451
[TBL] [Abstract][Full Text] [Related]
16. Antibiotic strategies for eradicating Pseudomonas aeruginosa in people with cystic fibrosis.
Langton Hewer SC; Smith S; Rowbotham NJ; Yule A; Smyth AR
Cochrane Database Syst Rev; 2023 Jun; 6(6):CD004197. PubMed ID: 37268599
[TBL] [Abstract][Full Text] [Related]
17. Prophylactic anti-staphylococcal antibiotics for cystic fibrosis.
Rosenfeld M; Rayner O; Smyth AR
Cochrane Database Syst Rev; 2020 Sep; 9(9):CD001912. PubMed ID: 32997797
[TBL] [Abstract][Full Text] [Related]
18. Oral anti-pseudomonal antibiotics for cystic fibrosis.
Remmington T; Jahnke N; Harkensee C
Cochrane Database Syst Rev; 2013 Oct; (10):CD005405. PubMed ID: 24170644
[TBL] [Abstract][Full Text] [Related]
19. Potentiators (specific therapies for class III and IV mutations) for cystic fibrosis.
Patel S; Sinha IP; Dwan K; Echevarria C; Schechter M; Southern KW
Cochrane Database Syst Rev; 2015 Mar; (3):CD009841. PubMed ID: 25811419
[TBL] [Abstract][Full Text] [Related]
20. Oral anti-pseudomonal antibiotics for cystic fibrosis.
Remmington T; Jahnke N; Harkensee C
Cochrane Database Syst Rev; 2016 Jul; 7(7):CD005405. PubMed ID: 27412131
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
